Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib

被引：0
|
作者：
Rogers, Kerry [1 ]
Lu, Xiaoxiao [2 ]
Emond, Bruno [3 ]
Ding, Zhijie [2 ]
Lefebvre, Patrick [3 ]
Lafeuille, Marie-Helene [3 ]
Mavani, Heena [2 ]
Qureshi, Zaina [2 ]
Ghosh, Nilanjan [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Janssen Sci Affairs, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Levine Canc Inst, Charlotte, NC USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; dose adjustment; real-world dosing; ibrutinib; chronic lymphocytic leukemia; outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-586
引用
下载
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [1] Real-world dosing patterns and outcomes in patients with chronic lymphocytic leukemia patients with or without dose adjustment of firstline ibrutinib
    Rogers, Kerry
    Lu, Xiaoxiao
    Edmond, Bruno
    Ding, Zhijie
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Mavani, Heena
    Qureshi, Zaina
    Ghosh, Nilanjan
    LEUKEMIA & LYMPHOMA, 2023, 64 : S169 - S170
  • [2] Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L).
    Rogers, Kerry Anne
    Lu, Xiaoxiao
    Emond, Bruno
    Ding, Zhijie
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Mavani, Heena
    Qureshi, Zaina P.
    Ghosh, Nilanjan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Qing Huang
    Kathleen L. Deering
    Qing Harshaw
    Lori A. Leslie
    Advances in Therapy, 2022, 39 : 3292 - 3307
  • [4] Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
    Huang, Qing
    Deering, Kathleen L.
    Harshaw, Qing
    Leslie, Lori A.
    ADVANCES IN THERAPY, 2022, 39 (07) : 3292 - 3307
  • [5] Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina
    He, Jinghua
    Qian, Yi
    Huang, Qing
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Jacobs, Ryan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S280 - S281
  • [6] Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database
    Ghosh, Nilanjan
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    He, Jinghua
    Mavani, Heena
    Qureshi, Zaina
    Rogers, Kerry
    LEUKEMIA & LYMPHOMA, 2023, 64 : S171 - S172
  • [7] Real-World Assessment of Dosing Patterns and Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia Who Initiated First-Line Single-Agent Ibrutinib in an Integrated Claims-Based Database
    Ghosh, Nilanjan
    Wang, Ruibin
    Ding, Zhijie
    Lu, Xiaoxiao
    He, Jinghua
    Mavani, Heena
    Qureshi, Zaina
    Rogers, Kerry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S329 - S330
  • [8] Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib
    Aarup, Kathrine
    Rotbain, Emelie Curovic
    Enggaard, Lisbeth
    Pedersen, Robert Schou
    Bergmann, Olav Jonas
    Thomsen, Rasmus Heje
    Frederiksen, Mikael
    Frederiksen, Henrik
    Nielsen, Tine
    Christiansen, Ilse
    Andersen, Michael Asger
    Niemann, Carsten Utoft
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (05) : 646 - 654
  • [9] Real-world outcomes following adverse events and dose reduction of first-line ibrutinib in Medicare beneficiaries with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Shadman, Mazyar
    Srivastava, Bhavini P.
    Salkar, Monika
    Saifan, Chadi
    Agatep, Barnabie C.
    Jones, Barton
    Ryan, Olga
    Bacchus, Shaffee
    Stephens, Deborah M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
    Challagulla, S.
    Lee, P.
    Kistler, K.
    Douyon, L.
    Lai, D.
    Iyengar, R.
    VALUE IN HEALTH, 2021, 24 : S38 - S38
12345